Work Here?
About Vial
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$65.2M
Headquarters
San Francisco, California
Founded
2020
Overview
Vial operates in the clinical trials market as a technology-driven Contract Research Organization (CRO). It helps pharmaceutical and biotechnology companies conduct clinical trials more efficiently and at a larger scale. Vial's main product is the Vial Technology Platform, which replaces traditional paper-based methods with connected systems and an intuitive design, allowing for smoother transitions between different trial phases and visits. This platform streamlines the entire clinical trial process. A key feature that sets Vial apart from its competitors is its fixed-fee pricing model, which provides clients with cost certainty and encourages the company to complete trials as efficiently as possible. Vial also contributes to the industry by publishing white papers on various topics related to clinical trials. The company's goal is to empower scientists to cure all human diseases by delivering faster and more efficient clinical trials.
Simplify's Take
What believers are saying
- Vial's partnership with Mason enhances remote management of clinical trial devices.
- The 'First in Human' podcast boosts Vial's brand visibility and industry influence.
- Vial's fixed-fee model maximizes ROI for clients, encouraging efficient trial completion.
What critics are saying
- Emerging competition from companies like Avicenna could challenge Vial's market position.
- Failure to integrate HEOR could affect the marketability of therapies developed by Vial.
- Rapid advancements in gene-editing technologies may require Vial to adapt its methodologies.
What makes Vial unique
- Vial uses a proprietary technology platform to streamline clinical trial processes.
- The company offers a fixed-fee pricing model, providing cost certainty for clients.
- Vial publishes industry-leading white papers, establishing thought leadership in clinical trials.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$65.2M
Above
Industry Average
Funded Over
1 Rounds
BoxGroup
General CatalystIndustry standards
Benefits
Unlimited PTO
Health, dental & vision
Paid parental leave
Remote-first culture
Competitive Equity Compensation
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 1%2 year growth
↑ 1%DURHAM, N.C.--(BUSINESS WIRE)--Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery. The company has raised $14.5 million in funding to date, with DCVC Bio leading its 2022 seed round, and this month published a paper in the peer-reviewed Journal of Chemical Information and Modeling. Co-authored with researchers from Schrödinger and Microsoft Research AI4Science, the paper outlines how combining Schrödinger’s physics-based methods with Avicenna’s novel ML methods can make the lead-to-drug optimization phase of small molecule drug discovery faster, less expensive and more successful – particularly when it comes to engineering potency and selectivity against a potential biological target.“We’re accustomed to hearing scientific success stories, but the countless failures that happen along the way often get overlooked. In medicinal chemistry especially, failure is prevalent. It can require hundreds of millions of dollars across many clinical attempts to bridge the complex gap from chemistry and biology to medicine, and successfully develop an approved drug,” said Dr. Thomas Kaiser, co-founder and Chief Scientific Officer at Avicenna
Pictured: A hand holding a bag of money and a pill bottle/Taylor Tieden for BioSpaceWhen biopharma companies test novel therapies in clinical trials, the primary focus of the research is on determining if the intervention works, with the goal of achieving FDA approval to enter the market. But there’s another part of clinical development that must not be neglected: health economics and outcomes research (HEOR), a multidisciplinary approach to evaluating the economic and clinical outcomes of healthcare interventions.Sponsors that skip this step could develop a safe and effective novel drug but fail to effectively commercialize it because payers don't recognize its cost/benefit improvement over existing options and do not cover it. Expensive therapies and diagnostics could therefore be out of reach for patients. Patients holding on to the promise of a new therapeutic solution are devastated, leading to negative sentiment against the sponsor. On the other hand, sponsors that demonstrate positive economic impact to payers early on could simultaneously bring their drug to market faster (without the requirement of additional studies) and to more patients at launch. Everybody wins.Even HEOR analysis that shows financial strain provides sponsors with vital data to inform the creation of drug pricing strategies and copay assistance programs to circumvent any negative consequences
Launching February 27, spring 2024 season exploresa new CRISPR therapy, advances in microbiome research, biotech for pets and moreWASHINGTON, Feb. 23, 2024 /PRNewswire/ -- On February 27, the Biotechnology Innovation Organization (BIO) premiers its Spring season of the I am BIO podcast with a discussion of new options for sickle cell patients. A groundbreaking treatment using CRISPR technology provides new hope for the nearly 100,000 Americans living with sickle cell disease – a disease and community that has been neglected for decades."The recent FDA gene-therapy approvals reflect breathtaking progress, not only for sickle cell patients, but also the biotech industry," said BIO's Chief Public Affairs and Marketing Officer, Rich Masters. "During this season of the podcast we uncover other amazing biotech innovations from new therapies based on the microbiome to advances in Alzheimer's treatments to the real meaning of 'organic.' Our podcast tells the biotech story—which is as intriguing and exciting as any murder mystery series!"Guests on the I AM BIO podcast are knowledgeable experts who explain the science in clear, engaging narratives. Each year the podcast releases 12 episodes – six in the spring and six beginning in September.This season, look forward to episodes on:The microbiome.The real meaning of "organic".Biotech for pets.New therapies for Alzheimer's.Questions from our audience.The podcast consistently lands on "top 10 biotech podcast" lists including Labiotech, Excedr, and Vial. Listen now on BIO's website, Apple Podcasts, Google Podcasts, or Spotify.About BIOBIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations
SAN FRANCISCO, Nov. 14, 2023 /PRNewswire/ -- Vial , a global tech-driven contract research organization (CRO) providing next-generation clinical trial management services, has announced its strategic partnership with Mason America Inc. ("Mason"), a provider of mobile infrastructure for smart hardware products. As part of the collaboration, Mason will provide Vial with hardware as a service for clinical sites, enabling remote management of devices for eSource at a global scale. This partnership empowers Vial to focus on accelerating the development of new therapies and devices for its sponsors and patients.Vial, led by CEO and Co-Founder Simon Burns, promises to deliver faster, more efficient trials for biotech sponsors while maintaining cost-effectiveness. The Vial CRO distinguishes itself by leveraging digital technology, such as its technology platform, combining eSource , EDC , and ePRO in one connected system to streamline site processes
SAN FRANCISCO, Sept. 24, 2023 /PRNewswire/ -- Vial , a global full-service CRO providing tech-forward clinical trial management services, announced its participation as a sponsor, exhibitor, and speaker at the 21st Precision in Clinical Trials Summit, taking place in San Diego, CA, on October 16-17, 2023, at the Westin San Diego Bayview.The summit serves as a platform for the largest bio-pharmaceutical hub in the region to network and discuss collaboration strategies aimed at achieving their outsourcing and operational goals. Attendees can look forward to an innovation-focused agenda, pre-scheduled meetings between potential collaborators, and access to a wide array of reliable solution providers. The summit is poised to provide attendees with the means to address their most pressing clinical trial challenges both in 2023 and beyond.Vial's Associate Business Development Director, John Sheperdson, Director of Business Development, Wade Berry, and Sales Development Representative, Gabriella Mills, will be representing the organization. Mr. Sheperdson will share insights into Vial's technological innovations and discuss the transformative potential of their solutions in the context of clinical trials on day 2 of the event at 9:50 AM (PST)."I'm thrilled to be part of the summit and represent Vial
There are no jobs for Vial right now.
Find jobs on Simplify and start your career today
About Vial
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$65.2M
Headquarters
San Francisco, California
Founded
2020
There are no jobs for Vial right now.
Find jobs on Simplify and start your career today